Skip to main content
Premium Trial:

Request an Annual Quote

T2 Biosystems Effects Reverse Stock Split, Reports 50 Percent Drop in Preliminary Q3 Revenues

NEW YORK – Infectious disease diagnostics firm T2 Biosystems said on Wednesday that its board of directors has approved a reverse stock split of its common stock at a ratio of one post-split share for every 50 pre-split shares. 

Each 50 shares of T2 Bio's common stock outstanding will be automatically combined into one share of common stock, the firm said in a statement. The stock split is intended to bring T2 Bio into compliance with the Nasdaq's minimum bid price requirement. T2 Bio received a letter from the Nasdaq in May saying the firm didn't meet the $1.00 minimum bid price requirement and could have its shares delisted. In June, the company was granted an extension until Nov. 1 to regain compliance with the requirement.

The split is effective Oct. 12, and the firm's common stock is expected to begin trading on a split-adjusted basis when the market opens on Oct. 13 under the existing ticker TTOO, the company added. 

Also on Wednesday, Lexington, Massachusetts-based T2 Bio announced its preliminary third quarter earnings. Estimated total revenue for the quarter is approximately $3.7 million, down 50 percent from Q3 2021, and estimated product revenue is about $2.6 million, down 40 percent from the year-ago quarter. The revenue decreases were driven by lower sales of COVID-19 tests and reduced revenue from the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority but were partially offset by increased sepsis test sales. Non-COVID-19 product revenue was about $2.3 million. 

The firm executed contracts for 11 T2Dx instruments during the quarter — three in the US and eight outside the US. Cash, cash equivalents, marketable securities, and restricted cash came to $21.5 million as of Sept. 30. 

T2 Bio also updated its full-year 2022 guidance, expecting total revenue of $22.0 million to $23.0 million and the closure of 50 to 55 T2Dx instrument contracts.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.